Skip to main content
. 2020 Jun 13;9(6):1846. doi: 10.3390/jcm9061846

Table 1.

Demographic characteristics of all study participants.

Schizophrenia a
(n = 39)
Bipolar Disorder b
(n = 37)
Healthy Controls c
(n = 32)
p Post-Hoc
(LSD)
Age (years) 43.62 ± 11.11 40.24 ± 12.72 44.59 ± 12.51 0.286
Sex 0.182
  Male 17 (43.6) 10 (27.0) 15 (46.9)
  Female 22 (56.4) 27 (73.0) 17 (53.1)
Premorbid IQ 100.60 ± 10.17 97.73 ± 8.19 107.03 ± 9.38 <0.001 a < c, b < c
Education (years) 13.28 ± 2.68 12.73 ± 2.70 13.59 ± 3.77 0.490
Number of hospitalizations 3.28 ± 4.09 2.47 ± 2.63 0.316
Duration of illness (years) 13.46 ± 9.54 9.50 ± 6.90 0.053
Onset age (years) 29.23 ± 10.71 30.94 ± 12.93 0.551
Dosage of medication
(CPZ equivalent, mg)
395.90 ± 480.77 253.53 ± 316.99
Dosage of medication
(equivalent to sodium
valproate dose, mg)
101.28 ± 250.39 790.49 ± 530.04
PANSS
  Positive 13.74 ± 7.16 8.95 ± 2.05
     Delusion 2.21 ± 1.51 1.16 ± 0.44
     Conceptual disorganization 2.23 ± 1.51 1.19 ± 0.52
     Hallucinatory behavior 2.23 ± 1.55 1.08 ± 0.36
     Excitement 1.54 ± 0.94 1.86 ± 0.86
     Grandiosity 1.49 ± 0.97 1.35 ± 0.72
     Suspiciousness/persecution 2.46 ± 1.39 1.57 ± 0.65
     Hostility 1.59 ± 0.85 1.19 ± 0.52
  Negative 17.28 ± 6.76 9.03 ± 2.69
  General 31.28 ± 10.91 24.03 ± 6.03
  Total 62.31 ± 22.22 42.00 ± 8.86
YMRS 5.78 ± 3.00
Verbal fluency 15.21 ± 4.95 14.57 ± 5.37 18.90 ± 5.96 0.003 a < c, b < c
K-AVLT-trial 5 8.77 ± 2.77 10.22 ± 2.84 11.50 ± 1.78 <0.001 a < b, a < c,
b < c

LSD: least significant difference; IQ: intelligence quotient; CPZ: chlorpromazine; PANSS: positive and negative syndrome scale; YMRS: Young Mania Rating Scale; K-AVLT: Korean Auditory Verbal Learning Test; a: schizophrenia; b: bipolar disorder; c: healthy controls.